Proteomics

Dataset Information

0

Acute pharmacological degradation of ERK5 does not inhibit cellular immune response or proliferation


ABSTRACT: Over the past few decades, interest in the role that extracellular signal-regulated kinase 5 (ERK5) plays in various diseases, particularly cancer and inflammation, has grown. Phenotypes observed from genetic knockdown or deletion of ERK5 suggested that targeting ERK5 could have therapeutic potential in various disease settings, motivating the development of potent and selective ATP-competitive ERK5 inhibitors. However, these inhibitors were unable to recapitulate the effects of genetic loss of ERK5, suggesting that ERK5 may have key kinase-independent roles. To investigate potential non-catalytic functions associated with ERK5, we report here the development of INY-06-061, a potent and selective heterobifunctional degrader of ERK5. In contrast to results reported through genetic knockdown of ERK5, INY-06-061-induced ERK5 degradation did not induce anti-proliferative effects in multiple cancer cell lines or suppress inflammatory responses in primary endothelial cells. Thus, we have developed and characterized a chemical tool useful for validating phenotypes reported to be associated with genetic ERK5 ablation and for guiding future ERK5-directed drug discovery efforts.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Suspension Culture

SUBMITTER: Eric Fischer  

LAB HEAD: Eric Fischer

PROVIDER: PXD036105 | Pride | 2022-10-13

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
esf_4638.raw Raw
esf_4639.raw Raw
esf_4640.raw Raw
esf_4641.raw Raw
esf_4642.raw Raw
Items per page:
1 - 5 of 25

Similar Datasets

2022-10-13 | PXD036104 | Pride
2023-05-29 | PXD040668 | Pride
2024-02-27 | PXD036614 | Pride
2016-09-09 | GSE86577 | GEO
2021-07-30 | PXD022021 | Pride
2021-07-30 | PXD022022 | Pride
2021-07-30 | PXD022060 | Pride
2021-07-30 | PXD022059 | Pride
2021-07-30 | PXD022058 | Pride
2022-03-11 | PXD025228 | Pride